[ACCESSWIRE]
WINNIPEG, MB / ACCESSWIRE / April 13, 2016 / Miraculins Inc. (TSXV: MOM) (the "Company") announces that it has changed its name to Luminor Medical Technologies Inc. and will commence trading on the TSX Venture Exchange under the new symbol "LMT" at the open of market on April 14, 2016. As previously announced on March 22, 2016, the Company has also completed a twenty-five to one (25 - 1) consolidation of its common shares resulting in the Company having approximately 2,020,656 common shares issued and outstanding as of April 14, 2016.
About Luminior Medical Technologies Inc.
Luminor Medical Technologies Inc. is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company's Scout DS® device has been regulatory cleared in certain markets as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes and type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.
For more information visit www.miraculins.com or contact:
Luminor Medical Technologies Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Scout DS® is a registered trademark of Luminor Medical Technologies Inc. All Rights Reserved. 2016.
SOURCE: Luminior Medical Technologies Inc.
